Exclusive Summary

• UB367 is an oral small molecule inhibitor targeting the mature IL-17A/F pathway, demonstrating inhibitory effects on both IL-17A and IL-17F with superior PK properties and safety profile.
• It offers differentiated advantages over existing biologics, including oral administration, higher cost-effectiveness, and broader application scenarios.
• The psoriasis market is substantial, with IL-17 targeted drugs already achieving multi-billion dollar annual sales, positioning UB367 to capture significant market share.
• Currently in the PCC stage, UB367 offers ample room for development and partnership opportunities.

Asset Materials

Contact Us for Full Materials